## **Medicare Chronic Condition Counts**

**Table B.2.b.** Medicare beneficiary prevalence\* for other chronic or disabling conditions\*\* using fee-for-service (FFS) claims, 2012–2021

| Totals             | 2012       | 2013       | 2014       | 2015       | 2016       |  |
|--------------------|------------|------------|------------|------------|------------|--|
| Total denominator† | 31,895,335 | 32,124,150 | 32,034,955 | 32,179,757 | 32,607,998 |  |

| Other chronic or disabling condition**  | 2012                   | 2012  | 2013                   | 2013  | 2014                   | 2014  | 2015                   | 2015  | 2016                   | 2016  |
|---|------------------------|-------|------------------------|-------|------------------------|-------|------------------------|-------|------------------------|-------|
|   | numerator <sup>‡</sup> | rate  |
| ADHD, conduct disorders, and hyperkinetic syndrome                                | 248,851                | 0.8%  | 271,841                | 0.8%  | 293,342                | 0.9%  | 317,658                | 1.0%  | 333,252                | 1.0%  |
| Alcohol use disorders   | 604,040                | 1.9%  | 632,009                | 2.0%  | 649,963                | 2.0%  | 698,051                | 2.2%  | 797,387                | 2.4%  |
| Anxiety disorders   | 3,721,714              | 11.7% | 4,134,362              | 12.9% | 4,435,133              | 13.8% | 4,814,382              | 15.0% | 5,346,168              | 16.4% |
| Autism spectrum disorders   | 43,617                 | 0.1%  | 49,486                 | 0.2%  | 55,314                 | 0.2%  | 62,340                 | 0.2%  | 71,621                 | 0.2%  |
| Bipolar disorder  | 1,033,503              | 3.2%  | 1,076,945              | 3.4%  | 1,098,958              | 3.4%  | 1,124,472              | 3.5%  | 1,155,688              | 3.5%  |
| Cerebral palsy  | 105,810                | 0.3%  | 107,704                | 0.3%  | 108,769                | 0.3%  | 110,363                | 0.3%  | 114,630                | 0.4%  |
| Cystic fibrosis and other metabolic developmental disorders                       | 155,189                | 0.5%  | 162,041                | 0.5%  | 174,283                | 0.5%  | 209,847                | 0.7%  | 260,333                | 0.8%  |
| Depressive disorders  | 4,927,609              | 15.4% | 5,111,608              | 15.9% | 5,258,316              | 16.4% | 5,425,067              | 16.9% | 5,516,712              | 16.9% |
| Drug use disorders  | 616,023                | 1.9%  | 665,110                | 2.1%  | 713,350                | 2.2%  | 818,499                | 2.5%  | 1,020,399              | 3.1%  |
| Epilepsy  | 805,605                | 2.5%  | 826,690                | 2.6%  | 834,433                | 2.6%  | 848,574                | 2.6%  | 893,338                | 2.7%  |
| Fibromyalgia, chronic pain, and fatigue   | 3,541,648              | 11.1% | 3,769,733              | 11.7% | 3,994,484              | 12.5% | 4,671,360              | 14.5% | 6,045,548              | 18.5% |
| Human immunodeficiency virus and/or acquired immunodeficiency syndrome (HIV/AIDS) | 119,958                | 0.4%  | 121,996                | 0.4%  | 121,620                | 0.4%  | 120,572                | 0.4%  | 121,653                | 0.4%  |
| Intellectual disabilities and related conditions                                  | 335,167                | 1.1%  | 339,466                | 1.1%  | 339,777                | 1.1%  | 342,665                | 1.1%  | 353,970                | 1.1%  |
| Learning disabilities   | 23,999                 | 0.1%  | 27,175                 | 0.1%  | 30,389                 | 0.1%  | 37,350                 | 0.1%  | 59,366                 | 0.2%  |
| Leukemias and lymphomas   | 440,672                | 1.4%  | 449,712                | 1.4%  | 460,919                | 1.4%  | 490,255                | 1.5%  | 534,535                | 1.6%  |
| Liver disease, cirrhosis, and other liver conditions, except hepatitis            | 1,086,714              | 3.4%  | 1,125,345              | 3.5%  | 1,167,318              | 3.6%  | 1,254,941              | 3.9%  | 1,393,667              | 4.3%  |
| Migraine and chronic headache   | 606,438                | 1.9%  | 655,760                | 2.0%  | 697,287                | 2.2%  | 780,849                | 2.4%  | 936,146                | 2.9%  |
| Mobility impairments  | 877,107                | 2.7%  | 871,941                | 2.7%  | 861,166                | 2.7%  | 873,355                | 2.7%  | 943,326                | 2.9%  |
| Multiple sclerosis and transverse myelitis  | 174,990                | 0.5%  | 180,051                | 0.6%  | 182,419                | 0.6%  | 185,538                | 0.6%  | 192,281                | 0.6%  |
| Muscular dystrophy  | 18,820                 | 0.1%  | 18,631                 | 0.1%  | 18,239                 | 0.1%  | 19,466                 | 0.1%  | 21,991                 | 0.1%  |
| Obesity   | 2,776,069              | 8.7%  | 3,183,579              | 9.9%  | 3,584,911              | 11.2% | 4,126,007              | 12.8% | 5,018,550              | 15.4% |
| Opioid use disorder   | 304,717                | 1.0%  | 347,027                | 1.1%  | 394,914                | 1.2%  | 484,905                | 1.5%  | 680,267                | 2.1%  |
| Other developmental delays  | 35,602                 | 0.1%  | 39,737                 | 0.1%  | 41,770                 | 0.1%  | 44,281                 | 0.1%  | 43,419                 | 0.1%  |

 ${\it Chronic Conditions Warehouse (CCW)-Your source for national CMS Medicare and Medicaid research data}\\$ 

Table B.2.b. Medicare beneficiary prevalence for other chronic or disabling conditions using fee-for-service (FFS) claims, 2012–2021 | Report run date: April 2023 Page 1 of 4

| Other chronic or disabling condition**                                       | 2012                   | 2012  | 2013                   | 2013  | 2014                   | 2014  | 2015                   | 2015  | 2016                   | 2016  |
|--|------------------------|-------|------------------------|-------|------------------------|-------|------------------------|-------|------------------------|-------|
|  | numerator <sup>‡</sup> | rate  |
| Peripheral vascular disease (PVD)  | 3,936,442              | 12.3% | 3,900,376              | 12.1% | 3,866,561              | 12.1% | 3,907,849              | 12.1% | 4,116,589              | 12.6% |
| Personality disorders  | 186,486                | 0.6%  | 191,261                | 0.6%  | 190,576                | 0.6%  | 257,830                | 0.8%  | 443,707                | 1.4%  |
| Post-traumatic stress disorder (PTSD)  | 236,583                | 0.7%  | 267,504                | 0.8%  | 295,920                | 0.9%  | 332,636                | 1.0%  | 373,316                | 1.1%  |
| Pressure and chronic ulcers  | 1,603,668              | 5.0%  | 1,594,872              | 5.0%  | 1,578,437              | 4.9%  | 1,565,032              | 4.9%  | 1,545,166              | 4.7%  |
| Schizophrenia  | 630,758                | 2.0%  | 629,540                | 2.0%  | 613,961                | 1.9%  | 604,093                | 1.9%  | 617,969                | 1.9%  |
| Schizophrenia and other psychotic disorders                                  | 1,307,122              | 4.1%  | 1,309,609              | 4.1%  | 1,303,002              | 4.1%  | 1,281,148              | 4.0%  | 1,151,629              | 3.5%  |
| Sensory — blindness and visual impairment                                    | 313,192                | 1.0%  | 301,718                | 0.9%  | 289,004                | 0.9%  | 264,081                | 0.8%  | 235,727                | 0.7%  |
| Sensory — deafness and hearing impairment                                    | 1,382,124              | 4.3%  | 1,483,259              | 4.6%  | 1,567,193              | 4.9%  | 1,657,088              | 5.1%  | 1,752,465              | 5.4%  |
| Sickle cell disease  | 14,525                 | 0.05% | 15,008                 | 0.05% | 14,521                 | 0.05% | 14,139                 | 0.04% | 14,187                 | 0.04% |
| Spina bifida and other congenital anomalies of the nervous system            | 50,487                 | 0.2%  | 50,777                 | 0.2%  | 50,651                 | 0.2%  | 51,010                 | 0.2%  | 50,979                 | 0.2%  |
| Spinal cord injury   | 91,670                 | 0.3%  | 92,145                 | 0.3%  | 90,357                 | 0.3%  | 118,350                | 0.4%  | 206,000                | 0.6%  |
| Tobacco use  | 2,501,295              | 7.8%  | 2,616,035              | 8.1%  | 2,691,524              | 8.4%  | 2,761,652              | 8.6%  | 2,779,411              | 8.5%  |
| Traumatic brain injury and nonpsychotic mental disorders due to brain damage | 131,127                | 0.4%  | 132,444                | 0.4%  | 134,358                | 0.4%  | 142,457                | 0.4%  | 149,500                | 0.5%  |
| Viral hepatitis (general)  | 374,445                | 1.2%  | 382,176                | 1.2%  | 385,477                | 1.2%  | 398,504                | 1.2%  | 418,630                | 1.3%  |

<sup>\*</sup> Includes all Medicare beneficiaries who were eligible for or enrolled in Medicare on or after January 1, YYYY. The Chronic Conditions Warehouse (CCW) team calculates period prevalence for these rates: beneficiaries with full or nearly full FFS coverage during the year who had claim(s) for the condition within the condition-specified lookback period (chronic conditions have a one- to five-year look-back period). Refer to the CCW website for more information, including algorithms, for these other chronic or disabling conditions.

**NOTE:** The application of different Medicare coverage restrictions/criteria will impact the size of these samples.

<sup>\*\*</sup> The CCW team may have counted beneficiaries in more than one chronic condition category.

<sup>†</sup> Denominator: Includes beneficiaries with full or nearly full FFS coverage (i.e., 11 or 12 months of Medicare Parts A and B [or coverage until time of death] and one month or less of health maintenance organization [HMO] coverage).

<sup>‡</sup> The CCW team defines numerator as evidence of claims for the condition.

Table B.2.b. Medicare beneficiary prevalence\* for other chronic or disabling conditions\*\* using fee-for-service (FFS) claims, 2012–2021

| Totals             | 2017       | 2018       | 2019       | 2020       | 2021       |  |
|--------------------|------------|------------|------------|------------|------------|--|
| Total denominator† | 32,483,529 | 32,184,841 | 31,860,990 | 31,187,299 | 29,757,982 |  |

| Other chronic or disabling condition**  | 2017                   | 2017  | 2018                   | 2018  | 2019                   | 2019  | 2020                   | 2020  | 2021                   | 2021  |
|---|------------------------|-------|------------------------|-------|------------------------|-------|------------------------|-------|------------------------|-------|
|   | numerator <sup>‡</sup> | rate  |
| ADHD, conduct disorders, and  | 328,301                | 1.0%  | 340,277                | 1.1%  | 347,061                | 1.1%  | 336,209                | 1.1%  | 316,221                | 1.1%  |
| hyperkinetic syndrome   |                        |       |                        |       |                        |       |                        |       |                        |       |
| Alcohol use disorders   | 739,505                | 2.3%  | 687,561                | 2.1%  | 681,687                | 2.1%  | 642,994                | 2.1%  | 593,791                | 2.0%  |
| Anxiety disorders   | 5,666,004              | 17.4% | 5,848,948              | 18.2% | 5,972,803              | 18.7% | 5,868,573              | 18.8% | 5,630,819              | 18.9% |
| Autism spectrum disorders   | 78,205                 | 0.2%  | 85,325                 | 0.3%  | 92,751                 | 0.3%  | 95,920                 | 0.3%  | 98,374                 | 0.3%  |
| Bipolar disorder  | 1,140,178              | 3.5%  | 1,138,082              | 3.5%  | 1,126,617              | 3.5%  | 1,074,815              | 3.4%  | 987,123                | 3.3%  |
| Cerebral palsy  | 116,529                | 0.4%  | 117,123                | 0.4%  | 116,665                | 0.4%  | 112,549                | 0.4%  | 106,508                | 0.4%  |
| Cystic fibrosis and other metabolic developmental disorders                       | 281,760                | 0.9%  | 294,437                | 0.9%  | 303,244                | 1.0%  | 294,266                | 0.9%  | 281,013                | 0.9%  |
| Depressive disorders  | 5,533,939              | 17.0% | 5,642,672              | 17.5% | 5,700,967              | 17.9% | 5,509,283              | 17.7% | 5,153,357              | 17.3% |
| Drug use disorders  | 1,132,782              | 3.5%  | 1,165,375              | 3.6%  | 1,177,261              | 3.7%  | 1,104,745              | 3.5%  | 995,801                | 3.3%  |
| Epilepsy  | 909,836                | 2.8%  | 906,696                | 2.8%  | 894,409                | 2.8%  | 854,038                | 2.7%  | 782,054                | 2.6%  |
| Fibromyalgia, chronic pain, and fatigue   | 6,969,392              | 21.5% | 7,258,130              | 22.6% | 7,354,751              | 23.1% | 6,969,755              | 22.3% | 6,658,296              | 22.4% |
| Human immunodeficiency virus and/or acquired immunodeficiency syndrome (HIV/AIDS) | 119,574                | 0.4%  | 115,415                | 0.4%  | 110,434                | 0.3%  | 104,305                | 0.3%  | 94,220                 | 0.3%  |
| Intellectual disabilities and related conditions                                  | 355,445                | 1.1%  | 356,057                | 1.1%  | 350,938                | 1.1%  | 333,342                | 1.1%  | 312,976                | 1.1%  |
| Learning disabilities   | 73,427                 | 0.2%  | 77,321                 | 0.2%  | 80,590                 | 0.3%  | 80,591                 | 0.3%  | 77,809                 | 0.3%  |
| Leukemias and lymphomas   | 551,245                | 1.7%  | 559,932                | 1.7%  | 569,515                | 1.8%  | 563,663                | 1.8%  | 555,743                | 1.9%  |
| Liver disease, cirrhosis, and other liver conditions, except hepatitis            | 1,507,103              | 4.6%  | 1,581,811              | 4.9%  | 1,647,361              | 5.2%  | 1,629,188              | 5.2%  | 1,625,084              | 5.5%  |
| Migraine and chronic headache   | 1,033,856              | 3.2%  | 1,075,914              | 3.3%  | 1,112,246              | 3.5%  | 1,076,400              | 3.5%  | 1,048,385              | 3.5%  |
| Mobility impairments  | 977,167                | 3.0%  | 969,610                | 3.0%  | 959,343                | 3.0%  | 916,267                | 2.9%  | 837,149                | 2.8%  |
| Multiple sclerosis and transverse myelitis  | 194,724                | 0.6%  | 193,738                | 0.6%  | 191,762                | 0.6%  | 184,657                | 0.6%  | 174,449                | 0.6%  |
| Muscular dystrophy  | 22,567                 | 0.1%  | 22,016                 | 0.1%  | 21,341                 | 0.1%  | 19,991                 | 0.1%  | 18,613                 | 0.1%  |
| Obesity   | 5,870,290              | 18.1% | 6,559,576              | 20.4% | 6,701,715              | 21.0% | 6,201,244              | 19.9% | 5,911,014              | 19.9% |
| Opioid use disorder   | 783,882                | 2.4%  | 778,761                | 2.4%  | 763,502                | 2.4%  | 702,583                | 2.3%  | 622,545                | 2.1%  |
| Other developmental delays  | 40,021                 | 0.1%  | 41,690                 | 0.1%  | 43,574                 | 0.1%  | 43,638                 | 0.1%  | 42,456                 | 0.1%  |
| Peripheral vascular disease (PVD)   | 4,113,394              | 12.7% | 4,120,466              | 12.8% | 4,161,955              | 13.1% | 4,005,703              | 12.8% | 3,758,217              | 12.6% |
| Personality disorders   | 516,426                | 1.6%  | 502,527                | 1.6%  | 486,044                | 1.5%  | 441,185                | 1.4%  | 387,502                | 1.3%  |
| Post-traumatic stress disorder (PTSD)   | 397,069                | 1.2%  | 420,994                | 1.3%  | 439,409                | 1.4%  | 429,345                | 1.4%  | 401,428                | 1.3%  |

 ${\it Chronic Conditions Warehouse (CCW)-Your source for national CMS Medicare and Medicaid research data}\\$ 

Table B.2.b. Medicare beneficiary prevalence for other chronic or disabling conditions using fee-for-service (FFS) claims, 2012–2021 | Report run date: April 2023 Page 3 of 4

| Other chronic or disabling condition**                                       | 2017                   | 2017  | 2018                   | 2018  | 2019                   | 2019  | 2020                   | 2020  | 2021                   | 2021 |
|--|------------------------|-------|------------------------|-------|------------------------|-------|------------------------|-------|------------------------|------|
|  | numerator <sup>‡</sup> | rate  | numerator <sup>‡</sup> | rate |
| Pressure and chronic ulcers  | 1,508,930              | 4.6%  | 1,506,601              | 4.7%  | 1,503,293              | 4.7%  | 1,471,726              | 4.7%  | 1,392,743              | 4.7% |
| Schizophrenia  | 610,488                | 1.9%  | 596,169                | 1.9%  | 573,787                | 1.8%  | 541,353                | 1.7%  | 487,314                | 1.6% |
| Schizophrenia and other psychotic disorders                                  | 1,030,212              | 3.2%  | 987,563                | 3.1%  | 940,228                | 3.0%  | 879,982                | 2.8%  | 784,276                | 2.6% |
| Sensory — blindness and visual impairment                                    | 205,415                | 0.6%  | 170,617                | 0.5%  | 146,426                | 0.5%  | 144,198                | 0.5%  | 131,524                | 0.4% |
| Sensory — deafness and hearing impairment                                    | 1,828,861              | 5.6%  | 1,916,241              | 6.0%  | 1,997,233              | 6.3%  | 1,907,277              | 6.1%  | 1,891,688              | 6.4% |
| Sickle cell disease  | 13,813                 | 0.04% | 13,283                 | 0.04% | 12,723                 | 0.04% | 12,075                 | 0.04% | 10,775                 | 0.0% |
| Spina bifida and other congenital anomalies of the nervous system            | 48,928                 | 0.2%  | 49,427                 | 0.2%  | 52,764                 | 0.2%  | 52,675                 | 0.2%  | 51,502                 | 0.2% |
| Spinal cord injury   | 246,624                | 0.8%  | 241,114                | 0.7%  | 243,131                | 0.8%  | 227,399                | 0.7%  | 212,746                | 0.7% |
| Tobacco use  | 3,031,387              | 9.3%  | 3,213,846              | 10.0% | 3,137,763              | 9.8%  | 2,841,035              | 9.1%  | 2,495,683              | 8.4% |
| Traumatic brain injury and nonpsychotic mental disorders due to brain damage | 150,098                | 0.5%  | 150,209                | 0.5%  | 148,476                | 0.5%  | 136,151                | 0.4%  | 121,153                | 0.4% |
| Viral hepatitis (general)  | 417,015                | 1.3%  | 398,665                | 1.2%  | 371,130                | 1.2%  | 328,954                | 1.1%  | 278,395                | 0.9% |

<sup>\*</sup> Includes all Medicare beneficiaries who were eligible for or enrolled in Medicare on or after January 1, YYYY. The Chronic Conditions Warehouse (CCW) team calculates period prevalence for these rates: beneficiaries with full or nearly full FFS coverage during the year who had claims(s) for the condition within the condition-specified look back period (chronic conditions have a one- to five-year look-back period). Refer to the CCW website for more information, including algorithms, for these other chronic or disabling conditions.

**NOTE:** The application of different Medicare coverage restrictions/criteria will impact the size of these samples.

<sup>\*\*</sup> The CCW team may have counted beneficiaries in more than one chronic condition category.

<sup>†</sup> Denominator: Includes beneficiaries with full or nearly full FFS coverage (i.e., 11 or 12 months of Medicare Parts A and B [or coverage until time of death] and one month or less of health maintenance organization [HMO] coverage).

<sup>‡</sup> The CCW team defines the numerator as evidence of claims for the condition.